Research ArticleAccepted Articles
Evaluation of patient and physician assessments of gastrointestinal disease activity in systemic sclerosis
Laura Ross, Susanna Proudman, Jennifer Walker, Wendy Stevens, Nava Ferdowsi, Alannah Quinlivan, Kathleen Morrisroe, Murray Baron and Mandana Nikpour
The Journal of Rheumatology November 2022, jrheum.220832; DOI: https://doi.org/10.3899/jrheum.220832
Laura Ross
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Susanna Proudman
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Jennifer Walker
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Wendy Stevens
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Nava Ferdowsi
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Alannah Quinlivan
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Kathleen Morrisroe
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Murray Baron
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Mandana Nikpour
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations. LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169). The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb. L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia. Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Article Information
jrheum.220832
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online November 15, 2022.
Article Versions
- You are currently viewing a Latest version of this article (November 15, 2022 - 04:00).
- latest version (December 15, 2022 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Laura Ross,
- Susanna Proudman,
- Jennifer Walker,
- Wendy Stevens,
- Nava Ferdowsi,
- Alannah Quinlivan,
- Kathleen Morrisroe,
- Murray Baron and
- Mandana Nikpour
-
The development of the Scleroderma Clinical Trials Consortium (SCTC) Activity Index has been supported by a Betty Z Benedict Award, SCTC Working Group Grants and private philanthropic donations.
LR is supported by a Musculoskeletal Australia PhD Scholarship and an Australian Government Research and Training Scholarship. MN is supported by a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538). KM holds a National Health and Medical Research Council of Australia Investigator Grant (APP 1197169).
The Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb.
L Ross: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; S Proudman: MBBS; Rheumatology Unit, Royal Adelaide Hospital, Adelaide Australia & Discipline of Medicine, University of Adelaide, Adelaide Australia; J Walker: MBBS, PhD; Rheumatology Unit, Flinders Medical Centre, Bedford Park Australia; W Stevens: MBBS; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; N Ferdowsi: MBBS, MMed; Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; A Quinlivan: MBBS; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; K Morrisroe: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia; M Baron: MDCM; Division of Rheumatology, Jewish General Hospital, McGill University, Montreal Canada; M Nikpour: MBBS, PhD; Department of Medicine, The University of Melbourne at St. Vincent's Hospital, Fitzroy Australia & Department of Rheumatology, St Vincent's Hospital, Melbourne, Fitzroy Australia.
Corresponding author: Dr Laura Ross, Departments of Rheumatology and Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Email: laura.ross@svha.org.au
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Evaluation of patient and physician assessments of gastrointestinal disease activity in systemic sclerosis
Laura Ross, Susanna Proudman, Jennifer Walker, Wendy Stevens, Nava Ferdowsi, Alannah Quinlivan, Kathleen Morrisroe, Murray Baron, Mandana Nikpour
The Journal of Rheumatology Nov 2022, jrheum.220832; DOI: 10.3899/jrheum.220832
Accepted manuscript
Evaluation of patient and physician assessments of gastrointestinal disease activity in systemic sclerosis
Laura Ross, Susanna Proudman, Jennifer Walker, Wendy Stevens, Nava Ferdowsi, Alannah Quinlivan, Kathleen Morrisroe, Murray Baron, Mandana Nikpour
The Journal of Rheumatology Nov 2022, jrheum.220832; DOI: 10.3899/jrheum.220832